Phosphatidylinositol 3-kinase (PI3K) inhibitors are a class of small molecule drugs that act by inhibiting the activity of PI3K enzymes, which play a key role in cell growth and survival. These inhibitors have been studied for their potential to treat a variety of diseases, including cancer and immune disorders. The chemical name of these inhibitors varies depending on the specific compound, but they share a similar mechanism of action. One example of a PI3K inhibitor is idelalisib, with CAS number 2504036-13-7.
The molecular formula of idelalisib is C22H18F3N5O, and its formula weight is 415.41 g/mol. It is sold under the trade name Zydelig and was approved by the FDA in 2014 for the treatment of certain types of lymphoma.
Top ten keywords from Google for PI3K inhibitors include:
Some synonyms for PI3K inhibitors include:
Health benefits of PI3K inhibitors depend on the specific disease being treated. In cancer, these inhibitors have shown promise in blocking the PI3K pathway, which is frequently activated in cancer cells and promotes tumor growth and survival. In immune disorders, PI3K inhibitors may help reduce inflammation and improve immune function.
Potential effects of PI3K inhibitors include reduced cell proliferation, induction of cell death, decreased inflammation, and enhanced anti-tumor immune responses. These effects vary depending on the specific compound and its target isoform(s).
The mechanism of action of PI3K inhibitors involves binding to the active site of PI3K enzymes, preventing them from catalyzing the conversion of phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-3,4,5-trisphosphate (PIP3). This results in decreased downstream signaling through the Akt/mTOR pathway, which plays a key role in cell growth and survival.
In terms of safety, PI3K inhibitors can cause side effects such as diarrhea, nausea, fatigue, and infections. More serious adverse events, such as liver toxicity and pneumonitis, have also been reported. Dosing information for PI3K inhibitors varies depending on the specific compound and indication.
In conclusion, PI3K inhibitors represent a promising class of small molecule drugs that hold potential for the treatment of cancer and immune disorders. Although they have shown efficacy in clinical trials, they can cause side effects and more research is needed to fully understand their long-term effects and optimal dosing regimens. Nonetheless, these inhibitors remain an important area of research and development in the field of oncology and immunology
